Prevention of cisplatin-induced ototoxicity

Prevention of cisplatin-induced ototoxicity refers to therapeutic strategies aimed at mitigating drug-induced inner ear damage in patients undergoing cisplatin-based chemotherapy

Prevention of cisplatin-induced ototoxicity refers to therapeutic strategies aimed at mitigating drug-induced inner ear damage in patients undergoing cisplatin-based chemotherapy Cisplatin accumulates in the cochlea, where it generates excessive reactive oxygen species, activates inflammatory and apoptotic pathways, and causes the selective and irreversible loss of outer hair cells, the stria vascularis, and spiral ganglion neurons

Cisplatin accumulates in the cochlea, where it generates excessive reactive oxygen species, activates inflammatory and apoptotic pathways, and causes the selective and irreversible loss of outer hair cells, the stria vascularis, and spiral ganglion neurons

Cisplatin accumulates in the cochlea, where it generates excessive reactive oxygen species, activates inflammatory and apoptotic pathways, and causes the selective and irreversible loss of outer hair cells, the stria vascularis, and spiral ganglion neurons

Clinically, this complication typically manifests as progressive, bilateral, sensorineural hearing loss—initially affecting high frequencies before progressing to conversational ranges—and may be accompanied by tinnitus

This protective indication is particularly critical in pediatric oncology populations, where chemotherapeutic hearing loss significantly impairs speech development, language acquisition, and cognitive outcomes

This protective indication is particularly critical in pediatric oncology populations, where chemotherapeutic hearing loss significantly impairs speech development, language acquisition, and cognitive outcomes